By Notice dated December 19, 2003, and published in the Federal Register on January 27, 2004, (69 FR 3946), Cambrex North Brunswick, Inc., Technology Center of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by letter to the Drug Enforcement Administration for registration as a bulk manufacturer of Sufentanil (9740), a basic class of Schedule II controlled substance.
The firm plans to manufacture Sufentanil to distribute in bulk to its customers.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Cambrex North Brunswick, Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Cambrex North Brunswick, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.
Dated: April 23, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 04-10801 Filed 5-11-04; 8:45 am]
BILLING CODE 4410-09-M